Anne-Sophie Grandvuinet

Senior Scientist at Symphogen

Anne-Sophie Grandvuinet has a diverse work experience in the pharmaceutical industry and research field. Anne-Sophie currently works as a Senior Scientist at Symphogen since 2021. Prior to this, they held various roles at Novo Nordisk, starting as a Research Scientist in 2012 and later becoming a Senior Development Professional in 2018. Anne-Sophie also worked as a Formulation Scientist at Novo Nordisk from 2015 to 2018.

Before joining Novo Nordisk, Anne-Sophie was a PhD Candidate at the Faculty of Pharmaceutical Sciences, University of Copenhagen from 2010 to 2013. Additionally, they had a brief role as a Visiting Research Fellow at UCSF in 2012.

Anne-Sophie's early career includes working as a Scientific Officer in the Consumer Safety Division at the Danish Medicines Agency from 2008 to 2009. Anne-Sophie also worked as a Student Assistant in the Licensing Division at the same agency from 2003 to 2007. In 2006, they briefly worked as a Student Assistant at the Pharmacy of Ryparken.

Anne-Sophie Grandvuinet completed their education in a chronological order. Anne-Sophie began their academic journey in 1987 at the Europeen School of Luxembourg, where they received their basic education. From 2001 to 2008, they attended Danmarks Farmaceutiske Universitet, where they obtained a Master of Science degree in Pharmacy with a focus on Pharmaceutical Sciences. Subsequently, they pursued their studies at the University of Melbourne from 2007 to 2008, where they completed a Master's thesis in the field of Pharmacology of Glutamate Transporters. Lastly, from 2010 to 2013, Anne-Sophie Grandvuinet earned a Doctor of Philosophy (PhD) degree in Pharmaceutical Sciences from Københavns Universitet - University of Copenhagen.

Location

Copenhagen, Denmark

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Symphogen

3 followers

Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.


Industries

Headquarters

Ballerup, Denmark

Employees

51-200

Links